Intradermal (ID) delivery has been shown to accelerate insulin pharmacokinetics (PK). We compared the PK and pharmacodynamic (PD) effects of insulin lispro administered before two daily standardized solid mixed meals (breakfast and lunch), using microneedle-based ID or traditional subcutaneous (SC) delivery.
Method:
The study included 22 subjects with type 1 diabetes in an eight-arm full crossover block design. One arm established each subject's optimal meal dose. In six additional arms, the optimal, higher, and lower doses (+30%, −30%) were each given ID and SC delivery, in random order. The final arm assessed earlier timing for the ID optimal dose (−12 versus −2 min). The PK/PD data were collected for 6 h following meals. Intravenous basal regular insulin was given throughout, and premeal blood glucose (BG) adjusted to 115 mg/dl.
Results:
The primary end point, postprandial time in range (70–180 mg/dl), showed no route-based differences with a high level of overall BG control for both SC and ID delivery. Secondary insulin PK end points showed more rapid ID availability versus SC across doses and meals (ΔTmax −16 min, ΔT50rising −7 min, ΔT50falling −30 min, all p < .05). Both intrasubject and intersubject variability for ID Tmax were significantly lower. Intradermal delivery showed modest, statistically significant secondary PD differences across doses and meals, generally within 90–120 min postprandially (Δ12 mg/dl BG at 90 min, Δ7 mg/dl BGmax, Δ7 mg/dl mean BG 0–2 h, all p < .05).
Conclusions:
This study indicates that ID insulin delivery is superior to SC delivery in speed of systemic availability and PK consistency and may improve postprandial glucose control.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329 (14): 977–86.
2.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.1998;352 (9131): 837–53.
3.
MonnierLMasEGinetCMichelFVillonLCristolJPColetteC. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA.2006;295 (14): 1681–7.
4.
BrownleeMHirschIB. Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications. JAMA.2006;295 (14): 1707–8.
5.
KilpatrickESRigbyASAtkinSL. A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the Diabetes Control and Complications Trial. Diabetes Care.2008;31 (11): 2198–202.
6.
CerielloAEspositoKPiconiLIhnatMAThorpeJETestaRBoemiMGiuglianoD. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes.2008;57 (5): 1349–54.
7.
WeberCSchnellO. The assessment of glycemic variability and its impact on diabetes-related complications: An overview. Diabetes Technol Ther.2009;11 (10): 623–33.
8.
HirschIBBrownleeM. Beyond hemoglobin A1c–need for additional markers of risk for diabetic microvascular complications. JAMA.2010;303 (22): 2291–2.
9.
De VegtFDekkerJMRuhéHGStehouwerCDNijpelsGBouterLMHeineRJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: The Hoorn Study. Diabetologia.1999;42 (8): 926–31.
10.
Temelkova-KurktschievTSKoehlerCHenkelELeonhardtWFueckerKHanefeldM. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care.2000;23 (12): 1830–4.
11.
DavidsonJ. Should postprandial glucose be measured and treated to a particular target? Yes. Diabetes Care.2003;26 (6): 1919–21.
12.
McCarterRJHempeJMChalewSA. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: An analysis of data from the Diabetes Control and Complications Trial. Diabetes Care.2006;29 (2): 352–5.
13.
KilpatrickESRigbyASAtkinSL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care.2006;29 (7): 1486–90.
14.
KilpatrickESRigbyASAtkinSL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care.2009;32 (10): 1901–3.
15.
BolliGB. Glucose variability and complications. Diabetes Care.2006;29 (7): 1707–9.
16.
RazIWilsonPWStrojekKKowalskaIBozikovVGittAKJermendyGCampaigneBNKerrLMilicevicZJacoberSJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial. Diabetes Care.2009;32 (3): 381–6.
17.
MonnierLLapinskiHColetteC. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care.2003;26 (3): 881–5.
18.
BergenstalRMTamborlaneWVAhmannABuseJBDaileyGDavisSNJoyceCPeoplesTPerkinsBAWelshJBWilliSMWoodMA; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med.2010;363 (4): 311–20.
19.
KovatchevBPBretonMManCDCobelliC. In silico preclinical trials: A proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol.2009;3 (1): 44–55.
El-KhatibFHRussellSJNathanDMSutherlinRGDamianoER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med.2010;2 (27): 27ra27.
22.
PhillipsNBWhittakerJIsmail-BeigiFWeissMA. Insulin fibrillation and protein design: Topological resistance of single-chain analogs to thermal degradation with application to a pump reservoir. J Diabetes Sci Technol.2012;6 (2): 277–88.
23.
SteinerSHompeschMPohlRSimmsPFlackeFMohrTPfütznerAHeinemannL. A novel insulin formulation with a more rapid onset of action. Diabetologia.2008;51 (9): 1602–6.
24.
HompeschMMcManusLPohlRSimmsPPfütznerABülowEFlackeFHeinemannLSteinerSS. Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol.2008;2 (4): 568–71.
25.
HeinemannLNosekLFlackeFAlbusKKrasnerAPichottaPHeiseTSteinerS. U-100, pH-Neutral formulation of VIAject(®): Faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab.2012;14 (3): 222–7.
26.
VaughnDEYocumRCMuchmoreDBSugarmanBJVickAMBilinskyIPFrostGI. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther.2009;11 (6): 345–52.
27.
MorrowLMuchmoreDBLudingtonEAVaughnDEHompeschM. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther.2011;13 (10): 1039–45.
28.
HompeschMMuchmoreDBMorrowLVaughnDE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care.2011;34 (3): 666–8.
29.
HompeschMMuchmoreDBMorrowLLudingtonEVaughnDE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther.2012;14 (3): 218–24.
30.
VaughnDEMuchmoreDB. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: Experience with subcutaneous injection and continuous infusion. Endocr Pract.2011;17 (6): 914–21.
31.
RazIWeissRYegorchikovYBittonGNagarRPesachB. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther.2009;31 (5): 980–7.
32.
EngwerdaEEAbbinkEJTackCJde GalanBE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care.2011;34 (8): 1804–8.
33.
RaveKPotockaEHeinemannLHeiseTBossAHMarinoMCostelloDChenR. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab.2009;11 (7): 715–20.
RaveKHeiseTPfütznerABossAH. Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care.2007;30 (9): 2307–8.
36.
RosenstockJLorberDLGnudiLHowardCPBilheimerDWChangPCPetrucciREBossAHRichardsonPC. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: A multicentre randomised trial. Lancet.2010;375 (9733): 2244–53.
37.
StoteRMarburyTShiLMillerMStrangeP. Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Technol.2010;4 (3): 603–9.
38.
StoteRMillerMMarburyTShiLStrangeP. Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. J Diabetes Sci Technol.2011;5 (1): 113–9.
39.
GuptaJFelnerEIPrausnitzMR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther.2011;13 (4): 451–6.
40.
HarveyAJKaestnerSASutterDEHarveyNGMiksztaJAPettisRJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res.2011;28 (1): 107–16.
41.
PettisRJGinsbergBHirschLSutterDKeithSMcVeyEHarveyNGHompeschMNosekLKapitzaCHeinemannL. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther.2011;13 (4): 435–42.
42.
GuptaJFelnerEIPrausnitzMR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther.2011;13 (4): 451–6.
43.
HarveyAJKaestnerSASutterDEHarveyNGMiksztaJAPettisRJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res.2011;28 (1): 107–16.
44.
PettisRJGinsbergBHirschLSutterDKeithSMcVeyEHarveyNGHompeschMNosekLKapitzaCHeinemannL. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther.2011;13 (4): 435–42.
45.
PettisRJHirschLKapitzaCNosekLHövelmannUKurthHJSutterDEHarveyNGHeinemannL. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: Pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabetes Technol Ther.2011;13 (4): 443–50.
46.
HarveyAJKaestnerSASutterDEHarveyNGMiksztaJAPettisRJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res.2011;28 (1): 107–16.
47.
SharmaRWangWRasmussenJCJoshiAHoustonJPAdamsKECameronAKeSKwonSMawadMESevick-MuracaEM. Quantitative imaging of lymph function. Am J Physiol Heart Circ Physiol.2007;292 (6): H3109–18.
48.
PettisRJHarveyAJ. Microneedle delivery: Clinical studies and emerging medical applications. Ther Delivery.2012;3 (3): 357–71.
49.
Sevick-MuracaEMSharmaRRasmussenJCMarshallMVWendtJAPhamHQBonefasEHoustonJPSampathLAdamsKEBlanchardDKFisherREChiangSBElledgeRMawadME. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: Feasibility study. Radiology.2008;246 (3): 734–41.
50.
StandlESchnellOCerielloA. Postprandial hyperglycemia and glycemic variability: Should we care?. Diabetes Care.2011;34Suppl 2: S120–7
